Mark S Winder, MD | |
32940 Pershing Road, Colombus, NM 88029 | |
(505) 531-2591 | |
Not Available |
Full Name | Mark S Winder |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 32940 Pershing Road, Colombus, New Mexico |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710102173 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 49781 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mark S Winder, MD Po Box 601, Columbus, NM 88029-0601 Ph: (505) 531-2591 | Mark S Winder, MD 32940 Pershing Road, Colombus, NM 88029 Ph: (505) 531-2591 |
News Archive
Risks of SARS-CoV-2 coronavirus infection for long-stay nursing home residents were mainly dependent on factors in their nursing homes and surrounding communities, according to a large study led by a researcher at the Johns Hopkins Bloomberg School of Public Health.
New research from the University of Southampton shows that removing confectionery and other unhealthy products from checkouts and the end of nearby aisles and placing fruit and vegetables near store entrances prompts customers to make healthier food purchases.
Whether triggered by cats, bees, pollen or mites, allergies are on the rise. And the bad news doesn't stop there. The only current therapy that treats their causes is allergen-specific immunotherapy - or allergy shots - which can cause severe side effects. Now, researchers report in Biomacromolecules the development of a potentially better allergy shot that uses nanocarriers to address these unwanted issues.
Researchers led by scientists at Dana-Farber Cancer Institute say they have identified unique genomic changes that may be integral to testicular cancer development and explain why the great majority are highly curable with chemotherapy - unlike most solid tumors.
Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.
› Verified 8 days ago